Phase 2 Study of Erlotinib in Combination with Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients with Non-small-cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
OSA obstructive sleep apnoea, AHI apnoea-hypopnea index, CPAP continuous positive airway pressure, SGLT2 sodium-glucose co-transporters 2, EMPA empagliflozin, DAPA dapagliflozin, ERTU ertugliflozin, LUSEO luseogliflozin, GLIME glimepiride, MET metformin, SDB sleep disordered breathing, ODI oxygen desaturation index, BW body weight, RR relative risk, LSpO 2 minimum oxygen saturation, ESS Epworth Somnolence Scale, HOMA-IR Homeostatic Model Assessment for Insulin Resistance, MED medication, Ref
De esta forma, aumenta la concentracin plasmtica de cidos grasos
Additionally, some physicians may see changes in their Medicare patient populations based on the new eligibility criteria, potentially affecting practice revenue